Search results

Found 30 pages
AUTHOR: Mark Greener

15 Oct 2007:

Prostate cancer treatment raises osteoporosis risk

Androgen deprivation therapy roughly doubles fracture risk in prostate cancer patients, BJU International reports. The study also showed that prostate cancer can increase fracture risk up to eight fold. - News - PharmaTimes

by Mark Greener

https://www.pharmatimes.com/news/prostate_cancer_treatment_raises_osteoporosis_risk_991117

10 Oct 2007:

Xeloda increases five-year survival in colon cancer

Roche’s Xeloda (capecitabine) increases the chance that patients with colon cancer will survive five years compared with conventional chemotherapy, according to newly released data from the University of Leeds. - News - PharmaTimes

by Mark Greener

https://www.pharmatimes.com/news/xeloda_increases_five-year_survival_in_colon_cancer_991082

1 Oct 2007:

Time to rethink clinical trials in diabetes

Most clinical trials assessing drugs for diabetes do not evaluate the medication’s impact on quality of life, the risk of developing complications or other outcomes that patients regard as important, argues a commentary in The Lancet this week. -

by Mark Greener

https://www.pharmatimes.com/news/time_to_rethink_clinical_trials_in_diabetes_990993

1 Nov 2007:

Shire set for fireworks with Mezavant XL

Shire will launch Mezavant XL, the first once daily mesalazine tablet, in the UK on 5 November. Mezavant XL is approved for the induction of clinical and endoscopic remission in mild to moderate, active ulcerative colitis. Mezavant XL is also

by Mark Greener

https://www.pharmatimes.com/news/shire_set_for_fireworks_with_mezavant_xl_991264

31 Oct 2007:

Statins may reduce prostate cancer relapse risk

Prostate cancer patients who receive high-dose radiotherapy and also take cholesterol-lowering statins are more likely to be free of the malignancy five and 10 years later than patients on radiotherapy alone, according to new research presented at

by Mark Greener

https://www.pharmatimes.com/news/statins_may_reduce_prostate_cancer_relapse_risk_991252

24 Sep 2007:

Serious adverse events: a growing problem

The number of serious adverse drug reactions reported in the US is growing at four times the rate of the number of prescriptions, according to the Archives of Internal Medicine. The increasing use of certain biopharmaceuticals and a minority of

by Mark Greener

https://www.pharmatimes.com/news/serious_adverse_events_a_growing_problem_990926

15 Oct 2007:

Statins could become new COPD treatment

Statins appear to slow the decline in lung function in elderly patients, even those who smoke, according to research published today in the American Journal of Respiratory and Critical Care Medicine. If confirmed, statins might become a new

by Mark Greener

https://www.pharmatimes.com/news/statins_could_become_new_copd_treatment_991108

8 Nov 2007:

Phase III data boost Roche’s Actemra in rheumatoid arthritis

Actemra, Roche’s first-in-class biopharmaceutical, is safe and effective in rheumatoid arthritis (RA), according to research presented this week at the American College of Rheumatology’s Annual Scientific Meeting in Boston, USA. - News -

by Mark Greener

https://www.pharmatimes.com/news/phase_iii_data_boost_roches_actemra_in_rheumatoid_arthritis_991327

11 Oct 2007:

Adjuvant chemo 'does not improve survival' in breast cancer

Adjuvant chemotherapy does not seem to improve long-term survival among women less than forty years of age with breast cancer, especially if their tumours respond to oestrogen, according to Breast Cancer Research. - News - PharmaTimes

by Mark Greener

https://www.pharmatimes.com/news/adjuvant_chemo_does_not_improve_survival_in_breast_cancer_991097

17 Sep 2007:

Making an IMPACT on clinical trial recruitment

Fewer than 2% of US cancer patients choose to participate in oncology trials. Increasing recruitment by just 2 to 3 percentage points could allow investigators to complete a typical study in two, instead of three, years. - News - PharmaTimes

by Mark Greener

https://www.pharmatimes.com/news/making_an_impact_on_clinical_trial_recruitment_990879